Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Two Advances On The Malaria Front

by Ann M. Thayer
December 15, 2008 | A version of this story appeared in Volume 86, Issue 50

[+]Enlarge
Credit: John-Michael Maas/Darby Communications
GlaxoSmithKline's malaria vaccine is advancing in clinical trials.
Credit: John-Michael Maas/Darby Communications
GlaxoSmithKline's malaria vaccine is advancing in clinical trials.

Pfizer and the Italian pharmaceutical company Sigma-Tau Industrie Farmaceutiche Riunite will market the antimalaria drug Eurartesim in Africa. Now in Phase III clinical studies, the therapy is a fixed-dose combination of dihydroartemisinin and piperaquine that was developed jointly by the nonprofit Medicines for Malaria Venture and Sigma-Tau. Separately, GlaxoSmithKline's RTS, S/AS vaccine continues to show promise in Phase II clinical trials by protecting a significant proportion of infants and young children against malaria. The results support the launch of a Phase III trial by GSK and the PATH Malaria Vaccine Initiative early next year. The Bill & Melinda Gates Foundation has invested nearly $108 million to support development. GSK has spent about $300 million to date and expects to invest up to $100 million more.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.